Alar Pharmaceuticals (ROCO:6785) ROCE % : -3.31% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Alar Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alar Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was -3.31%.

Alar Pharmaceuticals ROCE % Historical Data

The historical data trend for Alar Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alar Pharmaceuticals ROCE % Chart

Alar Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-30.07

-36.03

-11.31

-6.18

55.26

Alar Pharmaceuticals Quarterly Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial														0.87	238.91	4.07	1.28	-3.31

Alar Pharmaceuticals ROCE % Calculation

Alar Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	391.169	/	( ( (522.604 - 5.37)	+	(973.206 - 74.773) )	/ 2 )
	=	391.169	/	( (517.234	+	898.433)	/ 2 )
	=	391.169	/	707.8335
	=	55.26 %

Alar Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-82.044	/	( ( (2551.35 - 61.941)	+	(2522.911 - 53.975) )	/ 2 )
	=	-82.044	/	( ( 2489.409	+	2468.936 )	/ 2 )
	=	-82.044	/	2479.1725
	=	-3.31 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Alar Pharmaceuticals (ROCO:6785) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alar Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Alar Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alar Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alar Pharmaceuticals Inc (ROCO:6785) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 19, Keyuan Road, Rm. 312, 3rd Floor, Xitun District, Taichung, TWN, 407

Website

https://www.alarpharm.com

Alar Pharmaceuticals Inc is a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs.

Alar Pharmaceuticals Headlines

No Headlines